A previous study showed that activation of Nrf2 could ameliorate NAFLD through reducing oxidation and inhibiting the JNK pathway through treatment with osteocalcin and by improving NASH and hepatic fibrosis in a NASH model by suppressing ERs (Du et al., 2016; Sharma et al., 2018), which proved that Nrf2 could be a potential target for NAFLD. The gene discussed is MAPK8; the disease is metabolic dysfunction-associated steatotic liver disease.